Please assess the completion status of the following clinical trial:

Trial Title: A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* pancreatic cancer, surgically unresectable or with metastases;~* no previous chemotherapy (except concomitant with radiotherapy);~* ECOG 0-2.~Exclusion Criteria:~* pancreatic cancer without histologic or cytologic confirmation;~* surgical resection possible;~* previous chemotherapy not concomitant with radiotherapy;~* ECOG 3-4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).